Back to Search
ETHAN CORCORAN, M.D., PH.D.
M.D., PH.D.
Pulmonary Disease Physician
NPI: 1841417532IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
MD150309(OR)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
MD150309(OR)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
MD150309(OR)
CMS Specialties
PrimaryCRITICAL CARE (INTENSIVISTS)
Education
DUKE UNIVERSITY SCHOOL OF MEDICINE
Class of 2002
Research & Publications (16)
Proteomic analysis of calcium/calmodulin-dependent protein kinase I and IV in vitro substrates reveals distinct catalytic preferences.
PMID 12538590·J Biol Chem·2003
7-preclinical
Defining Ca2+/calmodulin-dependent protein kinase cascades in transcriptional regulation.
PMID 11096122·J Biol Chem·2001
6-review
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
PMID 19584274·Cancer Res·2009
7-preclinical
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
PMID 19528458·Anticancer Res·2009
7-preclinical
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
PMID 19252838·Methods Mol Biol·2009
7-preclinical
Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.
PMID 17954697·Antimicrob Agents Chemother·2008
7-preclinical
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
PMID 17085673·Clin Cancer Res·2006
7-preclinical
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
PMID 16641428·Antimicrob Agents Chemother·2006
7-preclinical
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
PMID 16609035·Clin Cancer Res·2006
4-observational
1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.
PMID 16246560·Bioorg Med Chem Lett·2006
7-preclinical
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
PMID 15767546·Mol Cancer Ther·2005
7-preclinical
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
PMID 15757893·J Biol Chem·2005
7-preclinical
A CaMK cascade activates CRE-mediated transcription in neurons of Caenorhabditis elegans.
PMID 12231504·EMBO Rep·2002
7-preclinical
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.
PMID 10898669·Antimicrob Agents Chemother·2000
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 10180 SE SUNNYSIDE RD
CLACKAMAS, OR 97015 - Phone
- (503) 571-2727
Quick Facts
- NPI
- 1841417532
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 24
- Publications
- 16
Are you this provider?
Claim Your Profile